Table 1.
Clinicopathological features of 12 FNH lesions and data of immunohistochemistry, clonality and LOH assays
| Case numbers | Age (yr)/gender | Lesion codes | Lesion sizes (cm) | Ki-67-LI (%) | p53-LI (%) | Clonality by XCIA | No. of LOH |
| 01 | 40/F | 011 | 5.0 | 1.6 | 0 | PC2 | 0 |
| 02 | 30/F | 02 | 2.5 | 0.5 | 0 | PC2 | 0 |
| 03 | 7.0 | 0.8 | 0 | PC2 | 0 | ||
| 03 | 22/M | 043 | 5.2 | 0.7 | 0 | NT | 0 |
| 04 | 44/M | 051 | 1.2 | 0.5 | 0 | NT | 0 |
| 05 | 31/F | 061 | 4.7 | 0.3 | 0 | PC2 | 0 |
| 06 | 43/F | 07 | 3.2 | 1.0 | 0 | PC2 | NT |
| 07 | 44/F | 081 | 2.0 | 0.8 | 0 | PC4 | NT |
| 08 | 53/F | 095 | 4.8 | 1.0 | 0 | PC2 | NT |
| 09 | 23/F | 101,5 | 4.5 | 1.2 | 0 | PC4 | NT |
| 10 | 46/F | 111,5 | 5.3 | 0.8 | 0 | PC3 | NT |
| 121 | 1.5 | 0.9 | 0 | PC4 | NT |
Some small preneoplastic foci, composed of clear cells, identified in surrounding liver parenchyma;
Tested on phosphoglycerate kinase (PGK) locus;
Nodules of altered hepatocytes (NAH) isolated from FNH by microdissection for LOH detection;
Noninformative at PGK locus and the data obtained by the assay on androgen receptor (AR) locus;
NAH isolated from FNH by microdissection for clonality assessment by XCIA. FNH: Focal nodular hyperplasia; Ki-67-LI: Ki-67 antigen-labeling indices; p53-LI: p53 protein-labeling indices by DO-7; XCIA: X-chromosomal inactivation assay; LOH: Loss of heterozygosity; F: Female; M: male; PC: Polyclonality; NT: Not tested for its origin from a male patient.